生物活性
NVP-BAW2881是有效的选择性VEGFR抑制剂(血管内皮生长因子受体酪氨酸激酶抑制剂),IC50 为值9 nM,具有抑制慢性和急性皮肤炎症的作用。
Targets
Target | Value |
TIE-2 | | |
hVEGFR2 | IC50: 9nM |
C-Raf-1 | IC50: 24nM |
B-RAFV599E | IC50: 76nM |
c-Abl | IC50: 99nM |
mVEGF2 | IC50: 165nM |
RET | IC50: 410nM |
hVEGFR3 | IC50: 420nM |
hVEGFR1 | IC50: 820nM |
c-KIT | IC50: 2.5μM |
化学数据
目录号 | A12693 |
作用机制 | Inhibitor (抑制剂) |
M. Wt | 424.1147 |
Formula | C22H15F3N4O2 |
Purity | >99% |
Storage | Store lyophilized at -20ºC, keep desiccated. In lyophilized form, the chemical is stable for36 months. In solution, store at -20ºC and use within3 monthsto prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles. |
CAS No. | 861875-60-7 |
Synonyms | BAW2881, BAW-2881, BAW 2881, NVP-BAW-2881, NVP-BAW 2881 |
SMILES | O=C(NC1=CC(C(F)(F)F)=CC=C1)C2=CC=CC3=C2C=CC(OC4=CC=NC(N)=N4)=C3 |
溶解度
In vitro | DMSO | 76 mg/mL (179.08 mM) |
Water | Insoluble |
Ethanol | 18 mg/mL |
*<1 mg/ml means slightly soluble or insoluble. *Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
储备液配制
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
0.1 mM | 23.58 mL | 117.89 mL | 235.79 mL |
0.5 mM | 4.72 mL | 23.58 mL | 47.16 mL |
1 mM | 2.36 mL | 11.79 mL | 23.58 mL |
5 mM | 0.47 mL | 2.36 mL | 4.72 mL |
*The above data is based on the productmolecular weight 424.1147. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.